Acta Scientific Nutritional Health (ASNH)(ISSN: 2582-1423)

Research Article Volume 5 Issue 7

Jasonia Montana; A Promising Therapeutic Agent to Attenuate Neurological Disorders Associated with SCO-induced Dementia

Mohammed A Hussein1*, Nada M El-Laban1, Lamiaa H Elabody1, Amany M Ghazal1, Basant S Mohamed1, Azhar A Mohamed1, Lamiaa Y Elhalafwy1, Sanaa M Elsayad1, Amal S Othman2 and Ali A Ali3

11Department of Biochemistry, Faculty of Applied Medical Science, October 6th University, Egypt
22Department of Med Labs, Faculty of Applied Medical Science, October 6th University, Egypt
33Vice President of Post Graduate Studies, October 6 University, Egypt

*Corresponding Author: Mohammed A Hussein, Professor of Biochemistry and Vice Dean for Post-graduate Studies and Scientific Research, Faculty of Applied Medical Sciences, October 6 University, Egypt.

Received: April 22, 2021; Published: June 11, 2021


Neurodegenerative disorder clinically characterized by progressive cognitive and memory dysfunction. This study investigated the effect of Jasonia montana ethanolic extract (JMEE) on Ca‑, Mg+2 and Na+, K+-ATPase and acetylcholinesterase (AChE) activities as well as β amyloid1-42 level in brain hippocampus of adult rats exposed to SCO. Rats were exposed to SCO (3.0 mg/Kg) and JMEE (150 mg/Kg) by gavage for 14 days. Rats were randomly divided into six groups with 6 rats in each: [Saline], [saline/SCO (3.0 mg/kg)], [saline/SCO (3.0 mg/kg)/JMEE (150 mg/kg,)], [saline/SCO (3.0 mg/kg)/ DHC (3 mg/kg)] and [saline/SCO (3.0 mg/kg)/JMEE (150 mg/kg,)/ DHC (3 mg/kg)]. Results demonstrated that plasma TC, TG as well as brain hippocampus levels of AChE, MAO, βA1-42, TBARS. Also, the results showed that a significant depletion of plasma HDL-C as well as brain hippocampus levels of phospholipids, GSH, ACh, Ca+2, Mg+2 and Na+, K+-ATPase. Treatment with JMEE (150 mg/Kg) prevented the increase in TC, TG, AChE, MAO, β amyloid1-42, TBARS activity when compared to SCO-treated group. JMEE treatment prevented the SCO-induced decrease in Ca+2, Mg+2 and Na+, K+-ATPase activities as well as GSH, HDL-C, ACh and phospholipids in SCO-treated group when compared to normal group. Our data showed that JMEE have a protector effect against SCO induced neurodegenerative. Also, Jasonia Montana is a promising therapeutic agent to attenuate neurological disorders associated with SCO induced dementia.

Keywords:Jasonia Montana; Antioxidant; Scopolamine; Acetylcholine Esterase; Monoamine Oxidase and Dementia


  1. Francis C., et al. “Beneficial effects of berry fruit polyphenols on neuronal and behavioral aging”. Journal of Agricultural and Food Chemistry 14 (2006): 2251-2255.
  2. Serrano-Pozo A., et al. “Neuropathological alterations in Alzheimer disease”. Cold Spring Harbor Perspectives in Medicine 1 (2011): a006189.
  3. Suh YH and Checler F. “Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s disease”. Pharmacology Review 54 (2002): 469-525.
  4. Birringer M. “Hormetics: dietary triggers of an adaptive stress response”. Pharmaceutical Research 11 (2011): 2680-2694.
  5. Koehn FE. “High impact technologies for natural products screening”. Progress in Drug Research 175 (2011): 177-210.
  6. Bantscheff M., et al. “Quantitative mass spectrometry in proteomics: a critical review”. Analytical and Bioanalytical Chemistry 389 (2007): 1017-1031.
  7. Choi YS., et al. “Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer’s disease biomarker candidates”. Journal of Chromatography A 930 (2013): 129-135.
  8. Chiasserini D., et al. “CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer’s disease”. Journal of Alzheimer's Disease 22 (2010): 1281-1288.
  9. Cruchaga C., et al. “Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer’s disease”. Human Molecular Genetics 21 (2012): 4558-4571.
  10. Wahrle SE., et al. “Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms”. Molecular Neurodegeneration 2 (2077): 7-13.
  11. Olsson B., et al. “Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer’s disease and vascular dementia”. Journal of Alzheimer's Disease 34 (2013): 673-679.
  12. Doody RS., et al. “Phase 3 trials of solanezumab for mildto-moderate Alzheimer’s disease”. The New England Journal of Medicine 370 (2014): 311-321.
  13. Liu Y., et al. “Biomarkers in Alzheimer’s disease analysis by mass spectrometry-based proteomics”. International Journal of Molecular Sciences 15 (2014): 7865-7882.
  14. Spencer JP. “Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain”. Proceedings of the Nutrition Society 2 (2010): 244-260.
  15. Andersen JK. “Oxidative stress in neurodegeneration: Cause or consequence?” Nature Medicine 10 (2004): S18-25.
  16. Ganesan A. “The impact of natural products upon modern drug discovery”. Current Opinion in Chemical Biology 3 (2008): 306-317.
  17. Koehn FE. “High impact technologies for natural products screening”. Progress in Drug Research 175 (2008): 177-210.
  18. Spires-Jones TL and Hyman BT. “The intersection of amyloid beta and tau at synapses in Alzheimer’s disease”. Neuron 82 (2014): 756-771.
  19. Haass C., et al. “Trafficking and proteolytic processing of APP”. Cold Spring Harbor Perspectives in Medicine 2 (2012): a006270.
  20. Tanzi RE. “The genetics of Alzheimer disease”. Cold Spring Harbor Perspectives in Medicine 2 (2012): 1-10.
  21. Merxmuller H., et al. In: J.B. Heywood J.B, Harborne B and Turner L. The Biology and Chemistry of Compositae. Academic Press, New York (1977): 590.
  22. Tackholm V. “Students Flora of Egypt”. Cairo University, Beirut (1974): 562.
  23. Tackholm V. “Alfred Kaiser’s Sinai-Herbarium”. Cairo University Herbium, Cairo (1969): 562.
  24. Ahmed AA and Jakupovic. “Sesqui and monoterpenes from Jasonia montana”. Phytochemistry 29 (1990): 3656-3661.
  25. Eid F., et al. “Constituents from Jasonia montana and Allagopuppus dicotoma”. Pharmazie 42 (1987): 423-24.
  26. Ahmed AA., et al. “11-Hydrojasionone A new sesquiterpene type from Jasonia montana”. Phytochemistry 27 (1988): 3875-3877.
  27. Ahmed AA. “Two geraniol derivatives from Jasonia montana”. Pharmazie 46 (1991): 362-63
  28. Ahmed AA., et al. “Flavonoid aglycones from Jasonia montana”. Phytochemistry 28 (1989): 665-667.
  29. El-gizawy HA and Hussein MA. “Fatty acids Profile, Nutritional Values, Anti-diabetic and Antioxidant Activity of the Fixed Oil of Malva parviflora Growing in Egypt”. International Journal of Phytomedicine 7 (2015): 219-230.
  30. Hussein MA. “Antidiabetic and antioxidant activity of Jasonia montana extract in streptozotocin-induced diabetic rats”. Saudi Pharmaceutical Journal 16 (2008): 3-4.
  31. Hussein MA and Farghaly HS. “Protective Effects of Jasonia montana Against Lipid Peroxidation in Liver and Kidney of Iron-overloaded Rats”. Australian Journal of Basic and Applied Sciences7 (2010): 2004-2012.
  32. Hussein MA and Abdelgawad S. “Protective effect of Jasonia montana against ethinylestradiol-induced cholestasis in rats”. Saudi Pharmaceutical Journal 18 (2010): 27-33.
  33. Hussein MA. “Anti-obesity, antiatherogenic, anti-diabetic and antioxidant activities of J. montana ethanolic formulation in obese diabetic rats fed high-fat diet”. Free Radicals and Antioxidants 1 (2011): 51-62.
  34. Hammerschmidt FJ., et al. “Chemical composition, and antimicrobial activity of essential oils of Jasonia candicans and Jasonia montana”. Planta Medica 59 (1993): 68-70.
  35. Milad R and Maliheh S. “Comparison of Memory Impairment and Oxidative Stress Following Single or Repeated Doses Administration of Scopolamine in Rat Hippocampus”. BCN 1 (2018): 5-14.
  36. Laxmi AP., et al. “Evaluation of neuroprotective effect of quercetin with donepezil in scopolamine-induced amnesia in rats”. Indian Journal of Pharmacology 1 (2017): 60-64.
  37. Fossati P and Prencipe L. “Plasma triacylglycerols determined calorimetrically with an enzyme that produces hydrogen peroxide”. Clinical Chemistry 1 (1982): 2077-2080.
  38. Allain CC., et al. “Enzymatic determination of total serum cholesterol”. Clinical Chemistry 4 (1974): 470-475.
  39. Friedewald WT. “Estimation of concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge”. Clinical Chemistry 18 (1972): 499-502.
  40. Tokeo S and Sakanashi M. “Characterization of membrane bound adenosine triphosphatase activity of enriched fraction from vascular smooth muscle”. Enzyme 34 (1985): 152-165.
  41. Bancroft GD and Steven A. “Theory and Practice of Histological Technique”. 4th ed. Churchill Livingstone, New York (1983): 99-112.
  42. Han XQ., et al. “Long-term fatty liver-induced insulin resistance in orotic acid-induced nonalcoholic fatty liver rats”. Bioscience, Biotechnology, and Biochemistry 4 (2016): 735-743.
  43. Liu XF., et al. “Eicosapentaenoic acid-enriched phospholipid ameliorates insulin resistance and lipid metabolism in diet-induced-obese mice”. Lipids in Health and Disease 12 (2013): Artn 109.
  44. Scicchitano P., et al. “Nutraceuticals and dyslipidaemia: Beyond the common therapeutics”. Journal of Functional Foods 6 (2014): 11-32.
  45. Quinn JF., et al. “Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial”. JAMA17 (2010): 1903-1911.
  46. Saw CLL., et al. “Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid”. Biochemical Pharmacology 3 (2010): 421-430.
  47. Abdalla FH., et al. “Neuroprotective effect of quercetin in ectoenzymes and acetylcholinesterase activities in cerebral cortex synaptosomes of cadmium-exposed rats”. Molecular and Cellular Biochemistry 381 (2013): 1-8.
  48. Safarinejad MR., et al. “Relationship of omega-3 and omega-6 fatty acids with semen characteristics, and anti-oxidant status of seminal plasma: a comparison between fertile and infertile men”. Clinical Nutrition1 (2010): 100-105.
  49. Sherif F., et al. “Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer’s disease”. Journal of Neural Transmission: Parkinson's Disease a and Dementia Section 3 (1992): 227-240.
  50. Gaweska H., et al. “Structures and mechanism of the monoamine oxidase family”. Biomolecular Concepts5 (2011): 365-377.
  51. Delgado PL., et al. “Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression”. Psychopharmacology Bulletin 3 (1991): 45-52.
  52. Cai Z. “Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer’s disease (Review)”. Molecular Medicine Reports 5 (2014): 1533-1541.
  53. Hroudová J., et al. “Progress in drug development for Alzheimer’s disease: An overview in relation to mitochondrial energy metabolism”. European Journal of Medicinal Chemistry 46 (2016): 165-174.
  54. Saada HN., et al. “Fish oil omega-3 fatty acids reduce the severity of radiation-induced oxidative stress in the rat brain”. International Journal of Radiation Biology 12 (2014): 1179-1183.
  55. Christian B., et al. “Chronic aspartame affects T‐maze performance, brain cholinergic receptors and Na+, K+‐ATPase in rats”. Pharmacology Biochemistry and Behavior 78 (2004): 121-127.
  56. Morris RG., et al. “Elements of a neurobiological theory of the hippocampus: the role of activity‐dependent synaptic plasticity in memory”. Philosophical Transactions of the Royal Society B 358 (2003): 773-786.
  57. Sato T., et al. “Effects of steroid hormones on (Na+, K+) ‐ATPase activity inhibition‐induced amnesia on the step‐through passive avoidance task in gonadectomized mice”. Pharmacology Research 49 (2004): 151-159.
  58. Scuri R., et al. “Inhibition of Na+/K+ ATPase potentiates synaptic transmission in tactile sensory neurons of the leech”. European Journal of Neuroscience 25 (2007): 159-167.
  59. Saini N., et al. “Neuroprotective effects of Bacopa monnieri in experimental model of dementia”. Neurochemistry Research 37 (2012): 1928-1937.
  60. Zhang L., et al. “Na (+)/K (+) ‐ATPase inhibition upregulates NMDA‐evoked currents in rat hippocampal CA1 pyramidal neurons”. Fundamental and Clinical Pharmacology 26 (2012): 503-512.
  61. Wang Y-M., et al. “Effects of different dietary phospholipids on lipid metabolism and brain phospholipids fatty acid composition in rats”. China Oils and Fats2 (2012): 31-34.
  62. Rogers SL., et al. “Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group”. Archives of Internal Medicine9 (1998): 1021-1031.
  63. Goh CW., et al. “Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats”. Drug Metabolism and Disposition: the Biological Fate of Chemicals3 (2011): 402-411.
  64. Boudrault C., et al. “Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer’s disease”. Journal of Nutritional Biochemistry 1 (2009): 1-10.
  65. Tackholm V. “Alfred Kaiser’s Sinai-Herbarium, 1969 p. 562. Cairo University Herbium, Cairo. 21. Ahmed AA, Jakupovic. Sesqui and monoterpenes from Jasonia montana”. Journal of Phytochemistry 29 (1990): 3656-3661.
  66. Eid F., et al. “Constituents from Jasonia montana and Allagopuppus dicotoma”. Pharmazie 42 (1987): 423-24.
  67. Ahmed AA., et al. “Flavonoid aglycones from Jasonia montana”. Phytochemistry 28 (1989): 665-667.
  68. Ahmed AA. “Two geraniol derivatives from Jasonia montana”. Pharmazie 46 (1991): 362-363.
  69. Bouktaib, M. “Regio-and stereoselective synthesis of the major metabolite of quercetin, quercetin-3-O-b-D-glucuronide”. Tetrahedron Letters 43 (2002): 6263-6266.
  70. Graf B. “Flavonols, flavones, flavanones, and human health: epidemiological evidence”. Journal of Medicinal Food 8 (2008): 281-290.
  71. Grune T and Berger MM. “Markers of oxidative stress in ICU clinical settings: present and future”. Current Opinion in Clinical Nutrition and Metabolic Care 17 (2007): 545-551.
  72. Ishisaka A., et al. “Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats”. Free Radical Biology and Medicine 51 (2011): 1329-1336.
  73. Dajas F. “Life or death: neuroprotective and anticancer effects of quercetin”. Journal of Ethnopharmacology 143 (2012): 383-396.


Citation: Mohammed A Hussein., et al. “Jasonia Montana; A Promising Therapeutic Agent to Attenuate Neurological Disorders Associated with SCO-induced Dementia".Acta Scientific Nutritional Health 5.7 (2021): 27-37.


Copyright: © 2021 Mohammed A Hussein., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.316

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US